01:28:18 (BST) 01:28:18 (BST)
CSE news on CENTRALPHL
2025-04-30: Un-audited Financial Statements
CENTRALPHL: (Quarter 3) As per un-audited financial statements of the Company, EPS was Tk. (0.10) for January-March 2025 as against Tk. (0.16) for January-March 2024; EPS was Tk. (0.24) for July 2024-March 2025 as against Tk. (0.31) for July 2023-March 2024. NOCFPS was Tk. 0.01 for July 2024-March 2025 as against Tk. (0.00) for July 2023-March 2024. NAV per share was Tk. 6.82 as on March 31, 2025 and Tk. 7.06 as on June 30, 2024.
2025-04-21: Board Meeting
CENTRALPHL: The Company has informed that the Board Meeting will be held on April 29, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
2025-01-30: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of the Company, EPS was Tk. (0.14) for October-December 2024 as against Tk. (0.09) for October-December 2023; EPS was Tk. (0.16) for July-December 2024 as against Tk. (0.15) for July-December 2023. NOCFPS was Tk. (0.00) for July-December 2024 as against Tk. (0.00) for July-December 2023. NAV per share was Tk. 6.89 as on December 31, 2024 and Tk. 7.06 as on June 30, 2024.
2025-01-23: Board Meeting
CENTRALPHL: The Company has informed that the Board Meeting will be held on January 29, 2025 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
2025-01-22: Qualified Opinion, Emphasis of Matter and Other Matters
CENTRALPHL: The auditor of the company has given the ''Qualified Opinion'', ''Emphasis of Matter'', and ''Other Matters'' paragraphs in the auditor's report for the year ended June 30, 2024. To view the details please visit: https://www.cse.com.bd/upload_media/CENRALPHL_2024.pdf
2024-11-26: Record Date Tomorrow (27.11.2024)
CENTRALPHL: Trading of the shares of the Company will remain suspended on its record date i.e., 27.11.2024. Trading of the shares of the Company will resume on 28.11.2024.
2024-11-21: Spot trade from 24.11.2024
CENTRALPHL: Trading of the shares of the Company will be allowed only in the Spot Market from 24.11.2024 to 26.11.2024 as the record date of the Company is on 27.11.2024.
2024-11-17: Un-audited Financial Statements
CENTRALPHL: (Quarter 1): As per un-audited financial statements of the Company, EPS was Tk. (0.004) for July-September 2024 as against Tk. (0.05) for July-September 2023; NOCFPS was Tk. (0.00) for July-September 2024 as against Tk. (0.00) for July-September 2023. NAV per share was Tk. 7.05 as on September 30, 2024 and Tk. 7.06 as on June 30, 2024.
2024-11-10: Board Meeting
CENTRALPHL: The Company has informed that the Board Meeting of the Company will be held on November 14, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
2024-11-05: Recommendation of No Dividend
CENTRALPHL: The Board of Directors has recommended No dividend for the year ended June 30, 2024. Date of AGM: 30.12.2024, Time: 11:30 AM, Venue: Hybrid, Hall Patio, Gulshan Club Limited, House# Nwj/2/A, Bir Uttom Sultan Mahmud Road, Gulshan-02, Dhaka-1212. Record date: 27.11.2024. The Company has also reported EPS of Tk. (0.35), NAV per share of Tk. 7.06 and NOCFPS of Tk. 0.02 for the year ended June 30, 2024 as against Tk. (0.37), Tk. 5.59 and Tk. (0.00) respectively for the year ended June 30, 2023.
2024-11-05: CB free
CENTRALPHL: Please note that there will be no price limit today 05.11.2024 on the trading of the shares of the company following its corporate declaration.
2024-10-30: Transfer of shares outside the Trading System of the Exchange
CENTRALPHL: Dhaka Stock Exchange PLC. (DSE) has accorded its consent to transfer total 21,825,000 shares of Central Pharmaceuticals Limited comprising 15,100,000 shares of Munsur Ahamed, a sponsor director of the company; 6,725,000 shares of Morsheda Ahmed, a sponsor director of the company to IDLC Investments Limited (the transferee) within 30 working days with effect from October 22, 2024 under Regulation 47 (1)(b) of the Dhaka Stock Exchange (Listing) Regulations, 2015 as per court order as well as other applicable laws.
2024-10-29: Reschedule of Board Meeting
CENTRALPHL: The Company has further informed that due to unavoidable circumstances, the Board meeting will be held on November 04, 2024 at 3:30 PM instead of October 28, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
2024-10-22: Board Meeting
CENTRALPHL: The Company has informed that the Board Meeting of the Company will be held on October 28, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
2024-09-26: Category Change
CENTRALPHL: The Company has been placed in 'Z' category from existing 'B' category with effect from September 26, 2024 as per provision 1(a) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024. The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase security of Central Pharmaceuticals Limited with effect from September 26, 2024 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
2024-05-02: Un-audited Financial Statements
CENTRALPHL: (Quarter 3) As per the un-audited financial statements of the Company, EPS was Tk. (0.16) for January-March 2024 as against Tk. (0.05) for January-March 2023; EPS was Tk. (0.31) for July 2023-March 2024 as against Tk. (0.19) for July 2022-March 2023. NOCFPS was Tk. (0.00) for July 2023-March 2024 as against Tk. (0.00) for July 2022-March 2023. NAV per share was Tk. 7.10 as on March 31, 2024 and Tk. 5.59 as on June 30, 2023.
2024-04-25: Board Meeting
CENTRALPHL: The Company has informed that the Board Meeting of the Company will be held on April 30, 2024 at 03:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
2024-02-08: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of the company, EPS was Tk. (0.09) for October-December 2023 as against Tk. (0.06) for October-December 2022; EPS was Tk. (0.15) for July-December 2023 as against Tk. (0.14) for July-December 2022. NOCFPS was Tk. 0.00 for July-December 2023 as against Tk. (0.00) for July-December 2022. NAV per share was Tk. 5.44 as on December 31, 2023 and Tk. 5.96 as on June 30, 2023.
2024-02-01: Reschedule of Board Meeting
CENTRALPHL: The Company has further informed that due to unavoidable circumstances the Board Meeting of the Company will be held on February 07, 2024 at 3:30 PM instead of January 31, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
2024-01-25: Board Meeting
CENTRALPHL: The Company has informed that the Board Meeting will be held on January 31, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
2023-11-22: Record Date tomorrow (23.11.2023)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will remain suspended on its record date i.e., 23.11.2023. Trading of the shares of the Company will resume on 26.11.2023.
2023-11-20: Spot trade from tomorrow (21.11.2023)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will be allowed only in the Spot Market from 21.11.2023 to 22.11.2023 as the record date of the Company is on 23.11.2023.
2023-11-20: CSE's Query Reply
CENTRALPHL: In response to CSE's query dated November 19, 2023, regarding the upward trend of its share price and volume, Central Pharmaceuticals Ltd. has informed that they have no undisclosed material decision/information relating to the company's operation/profitability that may impact on the price hike and trade volume of the shares of the company.
2023-11-15: Qualified Opinion
CENTRALPHL: The auditor of the company has given the "Qualified Opinion" paragraph in the Auditor's Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.cse.com.bd/upload_media/Qualified_Opinion_of_Central_Pharmaceuticals_Limited_for_the_year_ended_on_30_June_2023.pdf
2023-11-12: Un-audited Financial Statements
CENTRALPHL: (Quarter 1) As per un-audited financial statements of the Company, EPS was Tk. (0.05) for July-September, 2023 as against Tk. (0.08) for July-September, 2022. NOCFPS was Tk. (0.00) for July-September, 2023 as against Tk. 0.00 for July-September, 2022. NAV per share was Tk. 5.54 as on September 30, 2023 and Tk. 5.59 as on June 30, 2023.
2023-11-06: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 9, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
2023-11-05: CB free
CENTRALPHL: Please note that there will be no price limit today 05.11.2023 on the trading of the shares of the company following its corporate declaration. However, the floor price shall be applicable accordingly.
2023-11-05: Recommendation of No Dividend
CENTRALPHL: The Board of Directors has recommended No dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 11:30 AM, Venue: Digital Platform. Record date: 23.11.2023. The Company has also reported EPS of Tk. (0.37), NAV per share of Tk. 5.59 and NOCFPS of Tk. (0.00) for the year ended June 30, 2023 as against Tk. (0.57), Tk. 5.96 and Tk. (0.01) respectively for the year ended June 30, 2022.
2023-10-30: Reschedule of Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that due to unavoidable circumstances the Board Meeting of the Company will be held at November 02, 2023 at 3:00 pm instead of October 29, 2023 to consider, among others, audited financial statements of the Company for the year ended on June 30, 2023.
2023-10-23: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 29, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
2023-07-12: CSE's Query Reply
CENTRALPHL: In response to CSE's query dated July 11, 2023 regarding the upward trend of its share price and volume, Central Pharmaceuticals Ltd. has informed that they have no undisclosed material decision/information relating to the company's operation/profitability that may impact on the price hike and trade volume of the shares of the company.
2023-05-02: Un-audited Financial Statements
CENTRALPHL: (Quarter 3) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.05) for January-March 2023 as against Tk. (0.08) for January-March 2022; EPS was Tk. (0.19) for July 2022-March 2023 as against Tk. (0.26) for July 2021-March 2022. NOCFPS was Tk. (0.00) for July 2022-March 2023 as against Tk. (0.00) for July 2021-March 2022. NAV per share was Tk. 5.77 as on March 31, 2023 and Tk. 6.27 as on June 30, 2022.
2023-04-27: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
2023-03-01: Credit Rating
CENTRALPHL: Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity Rating (Initial) of Central Pharmaceuticals Ltd. as ''B1'' in the long term along with a stable outlook based on audited financial statements up to June 30, 2022; bank liability position up to September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2023-02-01: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of Central Pharmaceuticals Ltd., EPS was Tk. (0.06) for October-December 2022 as against Tk. (0.10) for October-December 2021; EPS was Tk. (0.14) for July-December 2022 as against Tk. (0.18) for July-December 2021. NOCFPS was Tk. (0.00) for July-December 2022 as against Tk. (0.00) for July-December 2021. NAV per share was Tk. 5.82 as on December 31, 2022 and Tk. 5.96 as on June 30, 2022.
2023-01-25: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 31, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
2022-11-24: Cont10-Qualified Opinion
CENTRALPHL(cont10): Factory Building, Plant and machinery & other equipment shows carrying value Taka 265,652,112 but Factory Building & most of the Plant and machinery which were found beyond their repairment stage. No impairment of assets was carried out in compliance with IAS-36. 19. We observed that the company consumed raw materials Taka 24,904,519 against sales of Taka 25,998,303. But management could not provide us proper evidence for excess raw materials consumption."(end)
2022-11-24: Cont9-Qualified Opinion
CENTRALPHL(cont9): 17. Unclaimed Cash Dividend payable shown Taka 859,383. And this amount was not transferred to capital market stabilization fund (CMSF) till November 03, 2022 as per BSEC Directive no. BSEC/CMRRCD/2021-391/20admin/121dated 1 June, 2021 18. We could not verify the appropriateness of book value of Property, Plant and equipment of the company shown in Note no-3 & Annexure-A to the Financial Statements. a) As per IAS 16, Property, Plant and equipment, revaluations should be carried out regularly so that carrying amount of assets does not differ materially from its fair value at the balance sheet date. Revaluation of land was made in 31 March, 2014.(cont10)
2022-11-24: Cont8-Qualified Opinion
CENTRALPHL(cont8): As a result, Assets and Liabilities have been overstated. 13. We could not obtain sufficient appropriate audit evidence for Inventories shown in Note no-5 to the Financial statements. We could not confirm the Inventories due to non-production of appropriate documents to us. 14. Net Sales have been shown Tk. 25,998,303 against which no proper documents could be provided to us. 15. No proper documents could be provided to us against purchase of raw materials Taka 8,082,891 and packing materials of Tk. 1,965,421. 16. No proper calculation could be provided to us against Deferred Tax. And no deferred tax have been calculated on revaluation reserve of land. (cont9)
2022-11-24: Cont7-Qualified Opinion
CENTRALPHL(cont7): But the company failed to show this amount Taka 6,366 in last year financial statement as on 30.6.2021. The company could not give explanations for not showing the balance in last year financial statement as on 30.6.2021. 12. No latest status on Tax assessment position of the company was provided. The National Board of Revenue (NBR) claimed taxes due Taka 988,245,451 for various assessment years from 2007 to 2021 as per letter no 178456845965/Circle-155/2021-2022 dated March 15, 2022. Advance Tax Tk. 286,267,503 and Provision for Tax Liabilities Tk. 280,023,373 remain unadjusted in the accounts as on 30.06.2022.(cont8)
2022-11-24: Cont6-Qualified Opinion
CENTRALPHL(cont6): 10. We observed that the company has been maintaining one bank account in Islami bank Bangladesh Limited, (Account no 20502090100378300, Shyamoli Branch). The company maintain all transaction by way of cash except transaction in Islami bank Bangladesh Limited (Account no 20502090100378300, Shyamoli Branch). Since the company maintain maximum cash transaction, there may have chance of over or under payment of expenses or over or under receipt of sales or income. 11. We also observed that Islami bank Bangladesh Limited (Account no 20502090100378300, Shyamoli Branch) were positive balance of Taka 6,366 as on 30.6,2021.(cont7)
2022-11-24: Cont5-Qualified Opinion
CENTRALPHL(cont5): 8. We could not obtain sufficient appropriate audit evidence for Other payables Taka 5,962,694 which was carried forwarded from last year. We could not confirm the amount due to non-production of necessary documents to us. 9. Three Bank Accounts of the company with Janata Bank Ltd. Local office, Dhaka were frozen by the Tax Authority demanding Tax Liability amount of Tk. 93,082,463 vide their letter no.178456845965/Circle-155/2014-2015/232 dated 26.04.2015 and no subsequent development thereof was reported. Since then, the company has been running through cash transactions.(cont6)
2022-11-24: Cont4-Qualified Opinion
CENTRALPHL(cont4): We could not confirm the amount Taka 287,701,679 due to non-production of necessary documents to us. We also could not send confirmation letter due to not producing address of Party. Since the amount carried forwarded from long time, recovery of advance is doubtful but no provision have been made for doubtful amount. 7. We could not obtain sufficient appropriate audit evidence for Sundry creditors Taka 1,499,174 for which no confirmation was given to us. We could not confirm the amount due to non production of necessary documents to us. We also could not send confirmation letter due to not producing address of Party.(cont5)
2022-11-24: Cont3-Qualified Opinion
CENTRALPHL(cont3): Since the amount carried forwarded from long time, recovery of accounts receivables is doubtful but no provision have been made for doubtful amount. 5. We could not obtain sufficient appropriate audit evidence for Spare parts & Supplies Taka 24,008,791 which was carried forwarded from last year. Since the amount carried forwarded from long time, the amount is doubtful but no provision have been made for doubtful amount. 6. Advance Deposits & prepayments shown Taka 287,812,844. Out of Taka 287,812,844 Taka 111,165 was paid for Advance income tax during the year. Rest amount Taka 287,701,679 which was carried forwarded from last year for which no confirmation was given to us. (cont4)
2022-11-24: Cont2-Qualified Opinion
CENTRALPHL(cont2): Since the company failed to pay loan installment in due time bank converted this loan as bad and loss. We also observed that bank charged interest Taka 17,357,468 on loan amount for nine months from July 01, 2021 to March 31, 2022. But bank did not charge interest for three months from April 2022 to June 30, 2022. The company did not make provision for three month interest. 4. We could not obtain sufficient appropriate audit evidence for Accounts Receivables Taka 79,100,617 for which no confirmation was given to us. We also could not send confirmation letter due to not producing address of Party.(cont3)
2022-11-24: Cont1-Qualified Opinion
CENTRALPHL(cont1): The financial statements do not adequately disclose this matter. 2. As per Financial Statements of June 30, 2021, Provision for tax liabilities shows Total taka 279,67,383 up to assessment years 2020-2021. But NBR claimed taxes due Taka 988,245,451 for various assessment years from (Assessment years 2007 to 2021) as per letter no 178456845965/Circle-155/2021-2022 dated March 15, 2022. But the company did not settle the issue with NBR and also the company did not maintain provisions for arrear tax liabilities for Taka 708,378,068. 3. The company has total bank loan Liabilities Taka 268,474,751 from Janata bank, local office, 1, Dilkusha, C/A as on June 30, 2022.(cont2)
2022-11-24: Qualified Opinion
CENTRALPHL: The auditor of the Central Pharmaceuticals Limited has given the "Qualified Opinion" paragraphs in the Auditor's Report for the year ended June 30, 2022. "Basis for Qualified Opinion: 1. The company has negative Retained earnings of Taka (999,022,598) as on June 30, 2022. And the company has failed to pay the loan installment in due time and also the loan amount Taka 268,474,751 is considered as Bad and loss by the bank. The company could not arrange any fund to repay the loan and the operating cash flow of the company is negative. These events or conditions, along with other matters indicate that a material uncertainty exist that may cast significant doubt on the company's ability to continue as a going concern.(cont1)
2022-11-23: Record Date tomorrow (24.11.2022)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will remain suspended on its record date i.e., 24.11.2022. Trading of the shares of the Company will resume on 27.11.2022.
2022-11-21: Spot trade from tomorrow (22.11.2022)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will be allowed only in the Spot Market from 22.11.2022 to 23.11.2022 as the record date of the Company is on 24.11.2022.
2022-11-16: Un-audited Financial Statements
CENTRALPHL: (Quarter 1) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.08) for July-September, 2022 as against Tk. (0.08) for July-September, 2021. NOCFPS was Tk. 0.00 for July-September, 2022 as against Tk. 0.00 for July-September, 2021. NAV per share was Tk. 5.88 as on September 30, 2022 and Tk. 5.96 as on June 30, 2022.
2022-11-09: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 15, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the company for the First Quarter (Q1) period ended September 30, 2022.
2022-11-06: CB free
CENTRALPHL: Please note that there will be no price limit today 06.11.2022 on the trading of the shares of the company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
2022-11-06: Recommendation of No Dividend
CENTRALPHL: The Board of Directors has recommended No dividend for the year ended on June 30, 2022. Date of AGM: 29.12.2022, Time: 11:30 AM, Venue: Digital Platform. Record date: 24.11.2022. The Company has also reported EPS of Tk. (0.57), NAV per share of Tk. 5.96 and NOCFPS of Tk. (0.01) for the year ended on June 30, 2022 as against Tk. (0.07), Tk. 6.53 and Tk. 0.01 respectively for the same period of the previous year.
2022-10-27: Reschedule of Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that due to unavoidable circumstances the Board Meeting of the Company will be held on November 03, 2022 at 3:30 PM instead of October 27, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
2022-10-23: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 27, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
2022-04-27: Un-audited Financial Statements
GHCL: (Quarter 3) As per un-audited financial statements of Global Heavy Chemicals Ltd., EPS was Tk. (0.20) for January-March 2022 as against Tk. 0.20 for January-March 2021; EPS was Tk. (0.68) for July 2021-March 2022 as against Tk. 0.60 for July 2020-March 2021. NOCFPS was Tk. 0.39 for July 2021-March 2022 as against Tk. 1.35 for July 2020-March 2021. NAV per share was Tk. 53.82 as on March 31, 2022 and Tk. 54.65 as on June 30, 2021. The Company has also informed that EPS has been decreased as sales have been decreased. NOCFPS has been decreased due to decrease of Sales and collection net cash provided by the operating activities.
2022-04-27: Un-audited Financial Statements
CENTRALPHL: (Quarter 3) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.08) for January-March 2022 as against Tk. (0.10) for January-March 2021; EPS was Tk. (0.26) for July 2021-March 2022 as against Tk. 0.06 for July 2020-March 2021. NOCFPS was Tk. 0.00 for July 2021-March 2022 as against Tk. (0.08) for July 2020-March 2021. NAV per share was Tk. 6.27 as on March 31, 2022 and Tk. 6.53 as on June 30, 2021.
2022-04-20: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 26, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
2022-01-31: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of Central Pharmaceuticals Ltd., EPS was Tk. (0.10) for October-December 2021 as against Tk. 0.08 for October-December 2020; EPS was Tk. (0.18) for July-December 2021 as against Tk. 0.16 for July-December 2020. NOCFPS was Tk. (0.00) for July-December 2021 as against Tk. 0.10 for July-December 2020. NAV per share was Tk. 6.35 as on December 31, 2021 and Tk. 6.53 as on June 30, 2021.
2022-01-24: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2022 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
2021-11-24: Record Date tomorrow (25.11.2021)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will remain suspended on its record date i.e., 25.11.2021. Trading of the shares of the Company will resume on 28.11.2021.
2021-11-22: Spot trade from tomorrow (23.11.2021)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will be allowed only in the Spot Market from 23.11.2021 to 24.11.2021 as the record date of the Company is on 25.11.2021.
2021-11-16: Un-audited Financial Statement
CENTRALPHL: (Quarter 1) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.08) for July-September, 2021 as against Tk. 0.08 for July-September, 2020. NOCFPS was Tk. 0.00 for July-September, 2021 as against Tk. (0.03) for July-September, 2020. NAV per share was Tk. 6.45 as on September 30, 2021 and Tk. 6.53 as on June 30, 2021.
2021-11-15: Cont8-Auditor's Opinion
CENTRALPHL(cont8):10. No proper calculation could be provided to us against Deferred Tax. 11. In note no 18 of the financial statement other payable includes TK. 688,096 of which no proper documents were provided to us. This amount is due in respect to cash dividend payable which is not disclosed as per BSEC Directive no. BSEC/CMRRCD/2021-386/03 dated 14 January 2021. Also the unclaimed dividend was not transferred to capital market stabilization fund (CMSF)."(end)
2021-11-15: Cont7-Auditor's Opinion
CENTRALPHL(cont7):It also appears that the Company has not distributed or utilized the Workers' Profit Participation Fund Tk. 13,744,387 of WPPF for a long period of time violating the Section 242 of the Bangladesh Labour Act, 2006 as amended 2013. The company did not form any Gratuity Fund (GF) and Provident Fund (PF) during the year or made any provision for the year. This is also non-compliance of the Bangladesh Labor Act, 2006 as amended 2013 as well as Employee Benefits (IAS-19). 9. No proper documents could be provided to us against addition of Property, Plant & Equipment.(cont8)
2021-11-15: Cont6-Auditor's Opinion
CENTRALPHL(cont6):6. Net Sales have been shown Tk. 140,091,702 against which no proper documents could be provided to us. 7. No proper documents could be provided to us against purchase of raw materials and packing materials of amounting Tk. 44,927,351 and Tk. 22,654,457. 8. Non-payment of Worker's Profit Participation Fund (WPPF) and Welfare Fund (WF): Constitution of management board and management of the fund regarding Workers Profit Participation Fund (WPPF) & Welfare Fund (WF) has not been maintained in accordance with the provision made in section 232 to 235 of the Bangladesh Labour Act, 2006 as amended 2013.(cont7)
2021-11-15: Cont5-Auditor's Opinion
CENTRALPHL(cont5):the management of the company has written off trade receivables of Tk. 583,386,646 during the year against which no supporting documents could be provided to us. As per the management, there were long cumulative outstanding amounts, untraceable medicine shops and medical officers, unadjusted returned expired products that were not accounted for in previous years which were taken into consideration in current year. However, no detailed calculation or supporting could be provided by the management on the balances written off. 5. In note no. 21 of the financial statements, amount of Tk. 3,152,249 was shown paid against Workers' Profit Participation Fund against which no proper documents were provided to us.(cont6)
2021-11-15: Cont4-Auditor's Opinion
CENTRALPHL(cont4):As existence or destruction of inventory was not justified by the company the actual value of inventory could not be determined or whether the loss incurred by them was correctly charged in cost of goods sold. 4. The balance of accounts receivable of Tk. 79,054,171 has increased from last year and is 53.3% of total sales reported during the year. No status report or confirmation certificate of lying balances with the concerned sales centers and parties could be provided to us. The company does not have any policy regarding recoverability of these receivables. Hence, recovery of accounts receivable was doubtful and no provision for bad debts was accounted for in last year. As per our qualification last year, (cont5)
2021-11-15: Cont3-Auditor's Opinion
CENTRALPHL(cont3):as movements of inventory were not recorded properly by the company. As per our qualification last year, the management of the company had written off inventory of Tk. 482,218,612 last year against which no supporting documents could be provided to us. As per the management, they have destroyed the inventory but no evidence could be provided on destruction. Neither were we informed before any such destruction done by the company. The value of inventory destroyed was charged in the cost of goods sold. The company could not provide proper evidence or justification for charging the loss incurred on inventory destruction in cost of goods sold.(cont4)
2021-11-15: Cont2-Auditor's Opinion
CENTRALPHL(cont2):The company has incurred loss for the year ended 30 June, 2021 but has made no provision for Turnover Tax on gross turnover of Tk. 148,151,797. Current tax provision should be Tk. 888,911 on turnover that was not provided for, due to which the current liabilities are understated by the same amount. 3. The volume of inventories was high in comparison to purchase, production capacity, cost of goods sold and turnover as a whole and is increased from last year of which no technical status report was provided to us on the quantity, quality and value of inventories. Physical existence with good condition and saleable value of major portion of inventories was doubtful,(cont3)
2021-11-15: Cont1-Auditor's Opinion
CENTRALPHL(cont1): The Tax Authority has a Claimed for 488,160,889 taka vide their letter No. Tax liability/A-13/Circle-155/2017-2018 dated 04.04.2018 that for the assessment years from 2007-2008 to 2016-2017. It was also found that Income Tax returns of the company for the assessment years 2017-2018 and 2018-2019 had been submitted on 22.10.2019 and tax assessment thereof have not been yet completed. Advance Tax Tk. 286,156,338 and Liabilities for Tax Tk. 279,867,383 remain unadjusted in the accounts. As a result, Assets and Liabilities have been overstated. No supporting documents as against payment of advance tax of Tk. 5,951,887 during the year 2019-2020 have been provided. (cont2)
2021-11-15: Auditor's Opinion
CENTRALPHL: The auditor of Central Pharmaceuticals Limited has given the "Qualified Opinion" in the audit report for the year ended on 30 June, 2021. "1. Three Bank Accounts of the company with Janata Bank Ltd. Local office, Dhaka were frozen by the Tax Authority demanding Tax Liability amount of Tk. 93,082,463 vide their letter no.178456845965/Circle-155/2014-2015/232 dated 26.04.2015 and no subsequent development thereof was reported. Since then, the company has been running through cash transactions. 2. No latest status on Tax assessment position of the company was provided.(cont1)
2021-11-10: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 15, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
2021-11-07: Recommendation of No Dividend
CENTRALPHL: The Board of Directors has recommended No dividend for the year ended on June 30, 2021. Date of AGM: 30.12.2021, Time: 11:30 AM, Venue: Digital Platform. Record date: 25.11.2021. The Company has also reported EPS of Tk. (0.07), NAV per share of Tk. 6.53 and NOCFPS of Tk. 0.01 for the year ended on June 30, 2021 as against Tk. (9.24), Tk. 6.60 and Tk. (0.00) respectively for the same period of the previous year.
2021-11-07: CB free
CENTRALPHL: Please note that there will be no price limit today 07.11.2021 on the trading of the shares of the company following its corporate declaration.
2021-10-28: Reschedule of Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has further informed that due to unavoidable circumstances, the Board Meeting of the Company will now be held on November 4, 2021 at 3:00 PM instead of October 28, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
2021-10-24: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 28, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
2021-08-03: Query Response
CENTRALPHL: In response to a DSE query dated August 02, 2021, Central Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
2021-06-15: Credit Rating
CENTRALPHL: WASO Credit Rating Company (BD) Ltd. (WCRCL) has announced the Rating of Central Pharmaceuticals Ltd. as ''BBB3'' in the long term and ''ST-4'' in the short term along with a stable outlook based on latest audited financial statements of the Company for FY20 and other relevant qualitative and quantitative information of the Company.
2021-05-24: Un-audited Financial Statements
CENTRALPHL: (Quarter 3) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.10) for January-March 2021 as against Tk. (0.18) for January-March 2020; EPS was Tk. 0.06 for July 2020-March 2021 as against Tk. (0.07) for July 2019-March 2020. NOCFPS was Tk. (0.08) for July 2020-March 2021 as against Tk. 0.09 for July 2019-March 2020. NAV per share was Tk. 6.66 as on March 31, 2021 and Tk. 6.60 as on June 30, 2020.
2021-05-02: Reschedule of Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has further informed that due to unavoidable circumstances the Board Meeting of the Company will be held on May 23, 2021 at 4:00 PM instead of April 29, 2021 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.
2021-04-25: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 29, 2021 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.
2021-01-31: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of Central Pharmaceuticals Ltd., EPS was Tk. 0.08 for October-December 2020 as against Tk. 0.04 for October-December 2019; EPS was Tk. 0.16 for July-December 2020 as against Tk. 0.11 for July-December 2019. NOCFPS was Tk. 0.10 for July-December 2020 as against Tk. 0.01 for July-December 2019. NAV per share was Tk. 6.76 as on December 31, 2020 and Tk. 6.60 as on June 30, 2020.
2021-01-25: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2021 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.
2020-12-20: Buy Intention
CENTRALPHL: Mrs. Morsheda Ahmed, one of the Directors of Central Pharmaceuticals Ltd., has reported her intention to buy 49,25,815 shares of the Company at prevailing market price (in the Public Market) through Stock Exchange (DSE) within next 30 working days.
2020-11-25: Record Date tomorrow (26.11.2020)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will remain suspended on its record date i.e., 26.11.2020. Trading of the shares of the Company will resume on 29.11.2020.
2020-11-23: Spot trade from tomorrow (24.11.2020)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will be allowed only in the Spot Market from 24.11.2020 to 25.11.2020 as the record date of the Company is on 26.11.2020.
2020-11-23: Cont6-Auditor's Opinion
CENTRALPHL(cont6): Hence, recovery of accounts receivable was doubtful and no provision for bad debts was accounted for in last year. 5. In note no. 21 of the financial statements, amount of Tk. 3,152,249 was shown paid against Workers' Profit Participation Fund against which no proper documents was provided to us. 6. Net Sales have been shown Tk. 140,091,702 against which no proper documents could be provided to us. 7.No proper documents could be provided to us against purchase of raw materials and packing materials of amounting Tk. 44,927,351 and Tk. 22,654,457."(end)
2020-11-23: Cont5-Auditor's Opinion
CENTRALPHL(cont5): unadjusted returned expired products that were not accounted for in previous years which were taken into consideration in current year. However, no detailed calculation or supporting could be provided by the management on the balances written off. As per our qualification last year, we observed that the balance of accounts receivable had been increasing years to years. No status report or confirmation certificate of lying balances of last year with the concerned sales centers and parties could be provided to us. The company did not have details of receivables or any policy regarding recoverability of these receivables.(cont6)
2020-11-23: Cont4-Auditor's Opinion
CENTRALPHL(cont4): Physical existence with good condition and saleable value of major portion of inventories was doubtful, as movement of inventory were not recorded properly by the company and no valid evidence were provided to us conforming the inventory or its net realizable value or any provision was made. 4. The management of the company has written off trade receivables of Tk. 583,386,646 during the year against which no supporting documents could be provided to us. As per the management, there were long cumulative outstanding amounts, untraceable medicine shops and medical officers, (cont5)
2020-11-23: Cont3-Auditor's Opinion
CENTRALPHL(cont3): The company could not provide proper evidence or justification for charging the loss incurred on inventory destruction in cost of goods sold. As existence or destruction of in inventory was not justified by the company the actual value of inventory could not be determined or whether the loss incurred by them was correctly charged in cost of goods sold. As per our qualification last year, we observed that the volume of inventories was high in comparison to purchase, production capacity, cost of goods sold and turnover as a whole and had been increasing years to years. No technical status report was provided to us on the quantity, quality and value of inventories last year.(cont4)
2020-11-23: Cont2-Auditor's Opinion
CENTRALPHL(cont2): The company has incurred loss for the year ended 30 June, 2020 but has made no provision for Turnover Tax on gross turnover of Tk. 140,091,702. Current tax provision should be Tk. 840,550 on turnover that was not provided for, due to which the current liabilities are understated by the same amount. 3.The management of the company has written off inventory of Tk. 482,218,612 during the year against which no supporting documents could be provided to us. As per the management, they have destroyed the inventory but no evidence could be provided on destruction. Neither were we informed before any such destruction done by the company. The value of inventory destroyed was charged in the cost of goods sold.(cont3)
2020-11-23: Cont1-Auditor's Opinion
CENTRALPHL(cont1): The Tax Authority has a Claimed for 488,160,889 taka vide there letter No. Tax liability/A-13/Circle-155/2017-2018 dated 04.04.2018 that for the assessment years from 2007-2008 to 2016-2017.It was also found that Income Tax returns of the company for the assessment years 2017-2018 and 2018-2019 had been submitted on 22.10.2019 and tax assessment thereof have not been yet completed. Advance Tax Tk. 280,204,451 and Liabilities for Tax Tk. 278,978,472 remain unadjusted in the accounts. As a result, Assets and Liabilities have been overstated. No supporting documents as against payment of advance tax of Tk. 9,078,904 during the year 2019-2020 have been provided.(cont2)
2020-11-23: Auditor's Opinion
CENTRALPHL: The auditor of Central Pharmaceuticals Limited has given the following "Qualified Opinion" in the audit report of the Company for the year ended on June 30, 2020. "Basis for Qualified Opinion: 1. Three Bank Accounts of the company with Janata Bank Ltd. Local office, Dhaka were frozen by the Tax Authority demanding Tax Liability amount of Tk. 93,082,463 vide their letter no. 178456845965/Circle -155/2014-2015/232 dated 26.04.2015 and no subsequent development thereof was reported. Sense then, the company has been running through cash transactions. 2. No latest status on Tax assessment position of the company was provided.(cont1)
2020-11-15: Un-audited financial statements
CENTRALPHL: (Quarter 1) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. 0.08 for July-September, 2020 as against Tk. 0.07 for July-September, 2019. NOCFPS was Tk. (0.03) for July-September, 2020 as against Tk. 0.01 for July-September, 2019. NAV per share was Tk. 6.68 as on September 30, 2020 and Tk. 6.60 as on June 30, 2020.
2020-11-09: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2020 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.
2020-11-05: CB free
CENTRALPHL: Please note that there will be no price limit today 05.11.2020 on the trading of the shares of the Company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.
2020-11-05: Recommendation of No Dividend
CENTRALPHL: The Board of Directors has recommended No dividend for the year ended on June 30, 2020. Date of AGM: 30.12.2020, Time: 11:30 AM, Venue: Digital Platform. Record date: 26.11.2020. The Company has also reported EPS of Tk. (9.24), NAV per share of Tk. 6.60 and NOCFPS of Tk. (0.00) for the year ended on June 30, 2020 as against Tk. 0.48, Tk. 14.87 and Tk. 0.09 respectively for the same period of the previous year.
2020-10-29: Reschedule of Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has further informed that, due to unavoidable circumstances, the Board Meeting of the Company will now be held on November 04, 2020 at 4:00 PM instead of October 28, 2020 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
2020-10-21: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 28, 2020 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
2020-10-06: Revised EPS for the Current period
CENTRALPHL: Referring to their earlier news disseminated by CSE on 07.06.2020 regarding (Quarter 3) Un-audited Financial Statements, Central Pharmaceuticals Ltd. has further informed that EPS for the period from Jan-March, 2020 would be Tk. (0.18) instead of Tk. (0.07) and EPS for the period from July 2019-March 2020 would be Tk. (0.07) instead of Tk. (0.18). The Company earlier mistakenly reported the EPS figures as mentioned above. Other information of the earlier disclosure will remain unchanged.
2020-07-16: Enquiry Committee formation by BSEC
CENTRALPHL: BSEC vide its Order No. BSEC/Surveillance/2020/930-104 dated July 16, 2020 has formed an enquiry committee to investigate into unusual movement of price and volume of shares of Central Pharmaceuticals Ltd. in the stock exchanges.
2020-06-07: Un-audited Financial Statements
CENTRALPHL: (Quarter 3) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.07) for January-March 2020 as against Tk. (0.01) for January-March 2019; EPS was Tk. (0.18) for July 2019-March 2020 as against Tk. 0.44 for July 2018-March 2019. NOCFPS was Tk. 0.09 for July 2019-March 2020 as against Tk. 0.06 for July 2018-March 2019. NAV per share was Tk. 15.73 as on March 31, 2020 and Tk. 14.87 as on June 30, 2019.
2020-06-01: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on June 06, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.
2020-03-23: Withdrawn the suspension of the license of production of few drugs
CENTRALPHL: Refer to their earlier news disseminated by CSE on March 05, 2020, Central Pharmaceuticals Ltd. has further informed that temporary suspension of the license of production of few drugs of the factory is withdrawn by Directorate General of Drug Administration (DGDA) on March 22, 2020.
2020-03-05: Query Response
CENTRALPHL: In response to DSE further query dated March 03, 2020 regarding clarification on recent news published in the daily newspaper, Central Pharmaceuticals Ltd. has informed that production of the factory is closed from December 05, 2019 as Directorate General of Drug Administration temporary suspended the license of production of few drugs.
2020-03-04: Query Response
CENTRALPHL: In response to a DSE query dated March 03, 2020, Central Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike of shares.
2020-02-02: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of Central Pharmaceuticals Ltd., EPS was Tk. 0.04 for October-December 2019 as against Tk. 0.15 for October-December 2018; EPS was Tk. 0.11 for July-December 2019 as against Tk. 0.44 for July-December 2018. NOCFPS was Tk. 0.01 for July-December 2019 as against Tk. 0.06 for July-December 2018. NAV per share was Tk. 16.01 as on December 31, 2019 and Tk. 14.87 as on June 30, 2019.
2020-01-30: Cash Dividend Disbursement
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2019 to the respective shareholders.
2020-01-23: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2020 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.
2019-11-27: Cont4-Auditor's Opinion
CENTRALPHL(cont4):5. The balance of accounts receivable has been increasing years to year. No latest status report thereof and confirmation certificate of lying balances as on 30 June, 2019 with the concerned sales centers and parties have been provided. The company does not have details of receivables or any policy regarding recoverability of these receivables. Hence, recovery of accounts receivable is doubtful, but no provision for bad debts has been accounted for."(end)
2019-11-27: Cont3-Auditor's Opinion
CENTRALPHL(cont3):as movement of inventory were not recorded properly by the company and no valid evidence were provided to us conforming of stock or its net realizable value no provision for written off the value of unsalable portion of inventories has been accounted for. 5. Long Term Loan has not been properly segregated into current portion and Long-Term portion, as a result Current Liabilities and Non-Current Liabilities not properly reflected in the financial statements. No calculation sheet on charged financial expenses and prior year adjustment for under charged interest has been provided.(cont4)
2019-11-27: Cont2-Auditor's Opinion
CENTRALPHL(cont2): Moreover, no supporting documents as against payment of advance tax of Tk. 18,097,893 during the year 2018-2019 have been provided. 3. The volume of inventories is so high in comparison to purchase, production capacity, cost of goods sold and turnover as a whole and has been increasing years to year. No technical status report as on 30 June, 2019 on the quantity, quality and value of inventories has been provided. And we could not also be able to verify the inventories physically as on 30 June, 2019 as we were appointed as auditors of the company on 05.10.2019. As such, physical existence with good condition and saleable value of major portion of inventories is doubtful,(cont3)
2019-11-27: Cont1-Auditor's Opinion
CENTRALPHL(cont1): Tax liability/A-13/Circle-155/2017-2018 dated 04.04.2018 that an accumulated amount of Tk. 488,160,889 was payable as tax liability as against the assessment years from 2007-2008 to 2016-2017. It was also found that IT returns of the company for the assessment years 2017-2018 and 2018-2019 were submitted on 22.10.2019 and tax assessment thereof not been completed. Accordingly, Advance Tax Tk. 271,125,547 and Liabilities for Tax Tk. 278,978,472 remain unadjusted in the accounts as a result Gross Assets and Gross Liabilities have been overstated.(cont2)
2019-11-27: Auditor's Opinion
CENTRALPHL: The auditor of Central Pharmaceuticals Ltd. has given the following qualified opinion in the audit report of the Company for the year ended on 30 June 2019: ''Basis for Qualified Opinion: 1. Three Bank Accounts of the company with Janata Bank Ltd. Local office, Dhaka were frozen by the Tax Authority demanding Tax Liability amount of Tk. 93,082,463 vide their letter no. 178456845965/Circle-155/2014-2015/232 dated 26.04.2015 and no subsequent development thereof was noticed. Accordingly, the company has been running through cash transactions since long. 2. No latest status on Tax assessment position of the company was provided and it was seen from a letter of the tax authority vide no.(cont1)
2019-11-24: Record Date tomorrow (25.11.2019)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will remain suspended on its record date i.e., 25.11.2019. Trading of the shares of the Company will resume on 26.11.2019.
2019-11-20: Spot trade from tomorrow (21.11.2019)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will be allowed only in the Spot Market from 21.11.2019 to 24.11.2019 as the record date of the Company is on 25.11.2019.
2019-11-17: Un-audited Financial Statements
CENTRALPHL: (Quarter 1) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. 0.07 for July-September, 2019 as against Tk. 0.29 for July-September, 2018. NOCFPS was Tk. 0.01 for July-September, 2019 as against Tk. 0.03 for July-September, 2018. NAV per share was Tk. 14.94 as on September 30, 2019 and Tk. 14.87 as on June 30, 2019.
2019-11-11: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2019 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.
2019-11-04: CB free
CENTRALPHL: Please note that there will be no price limit today 04 November 2019 on the trading of shares of the Company following its corporate disclosure.
2019-11-04: Recommendation of Dividend
CENTRALPHL: The Board of Directors has recommended 1% cash dividend for the year ended on June 30, 2019. Date of AGM: 30.12.2019, Time of AGM: 11:30 AM, Venue: HALL PATIO, Gulshan Club Limited, House # NWJ/2/A, Bir Uttom Sultan Mahmud Road (Old 50), Gulshan-2 Dhaka-1212. Record date: 25.11.2019. The Company has also reported EPS of Tk. 0.48, NAV per share of Tk. 14.87 and NOCFPS of Tk. 0.09 for the year ended on June 30, 2019 as against Tk. 0.51 (adjusted), Tk. 15.04 (adjusted) and Tk. 0.24 (adjusted) respectively for the same period of the previous year.
2019-10-28: Reschedule of Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has further informed that, due to illness of the Chairman of the company, the Board Meeting of the Company will now be held on November 03, 2019 at 4:00 PM instead of October 27, 2019 to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.
2019-10-20: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 27, 2019 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.
2019-05-08: Un-audited Financial Statement
CENTRALPHL: (Quarter 3) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. (0.01) for January-March 2019 as against Tk. 0.14 for January-March 2018; EPS was Tk. 0.44 for July 2018-March 2019 as against Tk. 0.29 for July 2017-March 2018. NOCFPS was Tk. 0.26 for July 2018 March 2019 as against Tk. 0.02 for July 2017-March 2018. NAV per share was Tk. 14.83 as on March 31, 2019 and Tk. 15.79 as on June 30, 2018.
2019-01-31: Un-audited HY A/Cs
CENTRALPHL: (Quarter 2) As per un-audited half yearly accounts of Central Pharmaceuticals Ltd., EPS was Tk. 0.16 for October-December 2018 as against Tk. 0.02 for October-December 2017; EPS was Tk. 0.47 for July-December 2018 as against Tk. 0.15 for July-December 2017. NOCFPS was Tk. 0.06 for July-December 2018 as against Tk. 0.02 for July-December 2017. NAV per share was Tk. 16.26 as on December 31, 2018 and Tk. 15.79 as on June 30, 2018.
2019-01-27: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.
2019-01-22: Transmission of Deceased Director's shares to her nominee
CENTRALPHL: Central Pharmaceuticals Limited has informed that Mrs. Nashima Akhter, one of the Directors of the Company passed away on 18.05.2018. Her present holding is 24,01,476 shares. These shares will be transmitted to the account of her nominee Mr. Munsur Ahamed, another Director of the Company; the younger brother of Late Mrs. Nashima Akhter by way of nomination.
2019-01-22: Bonus Shares Credited
CENTRALPHL: Central Pharmaceuticals Limited has informed that the Bonus Shares of the Company for the year ended on June 30, 2018 have already been credited through CDBL to the respective shareholders' BO A/Cs on 16 January 2019.
2019-01-03: BSEC Fined
CENTRALPHL: BSEC has imposed fine of Tk. 4.00 lac each to Mrs. Morsheda Ahmed (Director), Mr. Mansur Ahmed (Director), Mr. Md. Rokunuzzaman (Director), Mr. Parvez Ahmed Bhuiya (Director) and Mrs. Nasima Akhter (Director) of Central Pharmaceuticals Ltd. for non-compliance with the securities related laws.
2019-01-01: Category Change
CENTRALPHL: Please note that Central Pharmaceuticals Ltd. has been placed in ''B'' category from existing ''A'' category with effect from today 01 January 2019 as the Company has approved 5% stock dividend for the year ended on June 30, 2018. As per BSEC Directive No. SEC/CMRRCD/2009-193/177 and BSEC Order No. SEC/CMRRCD/2009-193/178 dated October 27, 2015; the stock brokers & merchant bankers are requested not to provide loan facilities to their clients against trading of the shares of CENTRALPHL up to 30 trading days from today 01 January 2019.
2018-12-09: Cont-Auditor's Opinion
CENTRALPHL(cont): IV. The Bank Accounts of the company has been frozen by the Tax Authority demanding Tax Liability Tk. 93,082,463. V. Advance Tax Tk. 253,027,654 and Liabilities for Tax Tk. 263,217,228 remain unadjusted in the accounts as a result Gross Assets and Gross Liabilities are overstated.''(end)
2018-12-09: Auditor's Opinion
CENTRALPHL: The auditor of Central Pharmaceuticals Ltd. has given the following qualified opinion in the audit report of the Company for the year ended on 30 June 2018: ''Basis of Qualified Opinion: I. Provision for Interest on Short Term Loan was not made in the accounts. II. Provision for Bad Debt was not made in the accounts. III. Long Term Loan has not been properly segregated into current portion and Long-Term Portion, as a result Current Liabilities and Non-Current Liabilities not properly reflected in the Financial Statements.(cont)
2018-11-26: Ex-benefit Price Adjustments
CENTRALPHL: Please note that the price of the shares of CENTRALPHL is adjusted today following its ex-benefits date to the extent of its corporate benefits; hence the price limit on the scrip will remain as it is today. Therefore, adjusted price of CENTRALPHL =Tk 16.10.
2018-11-22: Record Date on 25.11.2018
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will remain suspended on its record date i.e., 25.11.2018. Trading of the shares of the Company will resume on 26.11.2018.
2018-11-19: Spot trade from tomorrow (20.11.2018)
CENTRALPHL: Trading of the shares of Central Pharmaceuticals Ltd. will be allowed only in the Spot Market from 20.11.2018 to 22.11.2018 as the record date of the Company is on 25.11.2018.
2018-11-15: Un-audited Financial Statements
CENTRALPHL: (Quarter 1) As per the un-audited financial statements of Central Pharmaceuticals Ltd., EPS was Tk. 0.31 for July-September, 2018 as against Tk. 0.13 for July-September, 2017; NOCFPS was Tk. 0.03 for July-September, 2018 as against Tk. 0.02 for July-September, 2017. NAV per share was Tk. 16.10 as on September 30, 2018 and Tk. 15.79 as on June 30, 2018.
2018-11-11: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2018 at 2:45 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.
2018-10-28: CB free
CENTRALPHL: Please note that there will be no price limit today 28 October 2018 on the trading of shares of the Company following its corporate disclosure.
2018-10-28: Recommendation of Dividend
CENTRALPHL: The Board of Directors has recommended 5% stock dividend for the year ended on June 30, 2018. Date of AGM: 29.12.2018, Time of AGM: 11:30 AM, Venue: HALL PATIO, Gulshan Club Ltd., House # NWJ/2/A, Bir Uttom Sultan Mahmud Road (Old 50), Gulshan-2 Dhaka. Record date: 25.11.2018. The Company has also reported EPS of Tk. 0.53, NAV per share of Tk. 15.79 and NOCFPS of Tk. 0.25 for the year ended on June 30, 2018 as against Tk. 0.96 (adjusted), Tk. 15.26 (adjusted) and Tk. 0.18 (adjusted) respectively for the same period of the previous year.
2018-10-21: Board Meeting
CENTRALPHL: Central Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 27, 2018 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.
2018-10-11: Query Response
CENTRALPHL: In response to a DSE query dated October 09, 2018, Central Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike of shares
CSE News
©2024 Chittagong Stock Exchange PLC. All rights reserved.